Japan Market Entry
March 19, 2019

Historically, there has been a negative perception around the complexities and costs of developing drugs in Japan which has seen many innovators excluding it from their strategy and preventing Japanese patients being able to access the safest and most effective treatments.

The Japanese government have been working hard to change this and has implemented several systems to reward innovation resulting in a significant increase in the number of multi region clinical trials including Japan with growth at over 400% in the last 10 years.

This webinar will discuss some of the rewarding systems implemented by the government and regulatory considerations if developing in Japan, the second largest market in the world for branded pharmaceuticals.

Key take-aways:

  • Overview and changes in the Japanese regulatory environment
  • Regulatory considerations on international development strategy
  • Incentives and rewarding schemes for drug developers in Japan


Alan Thomas
Director, Thought Leadership, IQVIA Japan Group

Gen Uchida
Senior Director, Regulatory Affairs Management, IQVIA Japan Group